ArticleCurrent radiopharmaceuticals2025
Mitigation of Radiation-induced Acute Hematopoietic System and Intestine Injury by Resveratrol-loaded Polymeric Nanoparticles after Whole Body Irradiation in Mice.
Article in Current radiopharmaceuticals, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Unraveling the molecular landscape of chronic radiation injury: From oxidative stress signaling to translational modeling (Review).International journal of molecular medicine · 2026Review
- Protective effect of Zymosan-A against radiation-induced premature ovarian insufficiency in a murine model.iScience · 2026Article
- Radiomitigators: Breakthroughs in Post-Radiation Recovery.Antioxidants (Basel, Switzerland) · 2026Review
- A Modern Odyssey of Prevention: Integrating Nutrition and Lifestyle in Radiation Mitigation- A Narrative Review.Dose-response : a publication of International Hormesis SocietyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
introductionRadiation-induced damage to the hematopoietic and gastrointestinal systems, especially the intestine, is a major concern for individuals exposed to whole-body radiation during an accident. Resveratrol has shown potential in mitigating radiation-induced toxicity, but its efficacy may be limited by its low bioavailability. In this study, we aimed to evaluate the effectiveness of resveratrol-loaded polymeric-based nanocapsules in mitigating radiation-induced injury in the hematopoietic system and intestine after whole-body exposure to radiation.
methodsSixty male mice were randomly divided into four groups: control, radiation (single dose of 7.2 Gy of X-ray) only, resveratrol-loaded polymeric-based nanocapsules (RES-ACN) only, and radiation plus RES-ACN. Mice were exposed to a single dose of 7.2 Gy of X-ray radiation. RES-ACN was administered to the mice starting 24 h after irradiation up to day 7 post-irradiation. Then, blood and tissue samples were collected for complete blood count and histopathological and biochemical evaluation. Survival analyses were also conducted.
resultsThe findings showed that RES-ACN significantly mitigated radiation-induced injury to the hematopoietic system and intestine. The histopathological evaluation showed the mitigation of villi shortening, inflammation, and mucous layer thickness following treatment with RES-ACN. Biochemical evaluation also demonstrated a significant increase in the activity of glutathione peroxidase and superoxide dismutase and a significant reduction in the concentrations of malondialdehyde and nitric oxide. Treatment with RES-ACN also showed a significant improvement in some of the blood parameters and increased survival compared to radiation only.
conclusionThe findings suggest that resveratrol-loaded polymeric-based nanocapsules can be an effective approach to mitigate radiation-induced damage to the hematopoietic system and intestine after whole-body exposure to X-ray radiation in mice. Further research is needed to explore the optimal dose and timing of resveratrol administration and to investigate the potential for clinical translation of this approach.
Indexed as
Identifiers
39945267What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.